Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 261

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 261
---
ors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders
in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their
direct or indirect interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal
year ended December 31, 2023, which was filed with the SEC on May 15, 2024. Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available.
Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.
You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above.

NLS Contacts:

InvestorRelations@nls-pharma.com

www.nlspharma.com

Kadimastem Contacts:

Sarah Bazak, Investors
relations

s.bazak@kadimastem.com

www.kadimastem.com

Social Media: LinkedIn,
X, Facebook, Instagram

<div align='center'>4</div>